Hope Rugo, MD

This segment explores how ESR1 mutation testing may be integrated into clinical workflows for hormone receptor–positive, HER2-negative metastatic breast cancer.

This segment explores practical considerations for implementing ESR1 mutation testing in hormone receptor–positive, HER2-negative metastatic breast cancer, with a focus on testing strategy, frequency, and system-level constraints.

This segment explores increasing interest from both patients and clinicians in ctDNA testing and emerging targeted therapies in hormone receptor–positive, HER2-negative metastatic breast cancer.

This segment explores patient perspectives and acceptance of biomarker-driven treatment strategies in hormone receptor–positive, HER2-negative metastatic breast cancer.

This segment explores the growing role of genomic testing and multidisciplinary coordination in the management of hormone receptor–positive, HER2-negative metastatic breast cancer.

This segment explores deeper clinical interpretations of the SERENA-6 trial, particularly focusing on circulating tumor DNA dynamics and their relevance in hormone receptor–positive, HER2-negative metastatic breast cancer.

This segment focuses on the clinical implications of the SERENA-6 trial and its evaluation of circulating tumor DNA–guided treatment switching in hormone receptor–positive, HER2-negative metastatic breast cancer. Dr. Adam Brufsky introduces the trial within the context of ongoing regulatory and clinical debate regarding biomarker-driven intervention prior to radiographic progression.

This segment examines real-world access and reimbursement considerations influencing the use of oral selective estrogen receptor degraders in hormone receptor–positive, HER2-negative metastatic breast cancer.

This segment explores how emerging data on oral selective estrogen receptor degraders are being applied in clinical practice for hormone receptor–positive, HER2-negative metastatic breast cancer.

This segment introduces the evolving treatment landscape in hormone receptor–positive, HER2-negative metastatic breast cancer, with a focus on the growing clinical relevance of ESR1 mutations.

A panel of experts review ASCO 2024 and the need for future research in CDK4/6 inhibitors.

Dr. Dempsey discusses how CDK4/6 Inhibitors have impacted medication costs for breast cancer care, and the importance of implementing cost containment strategies to alleviate the situation.

Drs. Hanna and Rugo discuss possible access improvements in regards to CDK4/6 inhibitors.

Dr. O’Shaughnessy discusses how she weighs clinical benefits against cost considerations in regards to selecting a CDK4/6 inhibitor.

A panel of experts discuss the variables of dosage and patient adherence in regards to managing toxicities from CDK4/6 inhibitors.

A medical expert navigates toxicity management in patients being treated with ribociclib.

Dr. Rugo details her management strategy in regards to GI toxicities.

Dr. Dempsey details how different types of endocrine therapies have impacted toxicities within her patients.

A panel of experts compare the toxicity profiles of abemaciclib and ribociclib.